Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH)

NCT01613417 is registered in ClinicalTrials.gov with Bracco Diagnostics, Inc as lead sponsor.

NCT NCT01613417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01613417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV, Double-blind, Multi-center, Randomized, Crossover Study to Compare 0.1 mmol/kg of Prohance® With 0.1 mmol/kg of Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain (TRUTH)
Lead sponsor
Bracco Diagnostics, Inc
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2012
Completion date
April 30, 2014
Enrollment
229 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain disease